Patients with cancer are presumed to be at increased risk of severe COVID-19 outcomes
due to underlying malignancy and treatment-induced immunosuppression. Of the first 178 …

Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical
responses in a sizable minority of cancer patients. We found that primary resistance to ICIs …

Purpose To report updated analyses of the phase III CheckMate 214 trial with extended
minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab (…

Purpose Complete remission (CR) is uncommon during treatment for metastatic renal cell
carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs), but it may occur in some patients. It …

… Financial disclosures: Laurence Albiges certifies that all conflicts of interest, including … or
pending), are the following: Laurence Albiges received research grants from Pfizer and Novartis…

Background In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective
responses in patients with advanced renal-cell carcinoma. This phase 3 trial involving …

Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and
accounts for> 90% of cancers in the kidney. The disease encompasses> 10 histological and …

… Laurence Albiges has received consulting/advisory fees from BMS, Pfizer, Novartis, Sanofi,
Amgen, Bristol-Myers Squibb, Bayer, and Cerulean, and research funding from Pfizer and …

Background Cytoreductive nephrectomy has been the standard of care in metastatic renal-cell
carcinoma for 20 years, supported by randomized trials and large, retrospective studies. …

We report on molecular analyses of baseline tumor samples from the phase 3 JAVELIN
Renal 101 trial (n = 886; NCT02684006 ), which demonstrated significantly prolonged …